Arsenic trioxide - Phebra

Drug Profile

Arsenic trioxide - Phebra

Alternative Names: Phenasen

Latest Information Update: 15 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Phebra
  • Class Anti-inflammatories; Antineoplastics; Arsenicals; Ischaemic heart disorder therapies; Oxides; Small molecules
  • Mechanism of Action Apoprotein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute promyelocytic leukaemia
  • New Molecular Entity No

Highest Development Phases

  • Marketed Acute promyelocytic leukaemia

Most Recent Events

  • 14 Jun 2017 Phase-I clinical trials in Acute promyelocytic leukaemia (First-line therapy) in Australia, New Zealand (PO, Capsule) (ACTRN12616001022459)
  • 16 Mar 2017 Arsenic trioxide - Phebra (Capsule) receives Orphan Drug status for Acute promyelocytic leukaemia in Australia
  • 01 Jan 2017 Preclinical trials in Acute promyelocytic leukaemia in Australia (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top